Tackling the Opioid Epidemic

Chronic Opiate Analgesic Therapy (COAT) in a Primary Care Outpatient Clinic: Patient Perspective on Quality Improvement

Activity Details
  • Credit Amounts:
    • CME: 0.75
    • CNE: 1.00
    • Other: 0.75
  • Cost: Free
  • Release: Feb 27, 2017
  • Expires: Feb 26, 2020
  • Estimated Time to Complete:
    45 Minutes
  • System Requirements:
  • Average User Rating:
    (3 Ratings)

Faculty

Judith A.  Daniels Judith A. Daniels, PhD, APRN, FNP, PNP
Assistant Professor
University of Kentucky College of Nursing
Clinical Practitioner
Polk Dalton Internal Medicine/Pediatrics Clinic
Lexington, Kentucky

Needs Statement

Drug overdose is a huge problem facing the health care system in Kentucky. Drug overdose deaths are acute poisoning deaths due to prescription or illicit drugs. According to data from the National Center for Health Statistics, Kentucky had the 2nd highest drug overdose death rate in the US in 2013.

KENTUCKY INJURY PREVENTION AND RESEARCH CENTER http://www.mc.uky.edu/kiprc/ 
KENTUCKY DEPARTMENT FOR PUBLIC HEALTH http://chfs.ky.gov/dph/ 
Released October 2015

Patients are being denied or discontinued from opioids after years of receiving them due to provider fears and government warnings/limitations placed on prescribing. Providers need to know about new methods they can use to safely prescribe and approach chronic pain.

This activity has been approved by the KBML as meeting the statutory requirements of HB1. 

Target Audience

Health care professionals managing chronic pain in a primary care setting.

Objectives

Upon completion of this educational activity, participants will be able to:

  • Identify best practices for appropriate opioid prescription
  • Evaluate risks and potential benefits of opioids
  • Describe best practices for accurate dosing and discontinuation

Accreditation

CME
The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

ACGME Competencies

  • Patient care
  • Medical knowledge
  • Practice-based learning and improvement

CNE
The University of Kentucky, College of Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

This educational activity is offered for a maximum of 1.00 ANCC contact hour.

The Kentucky Board of Nursing (KBN) approves The University of Kentucky, College of Nursing (UKCON) as a provider as well. ANCC and KBN approval of a continuing nursing education provider does not constitute endorsement of program content nor commercial sponsors. The University of Kentucky does not approve commercial products. This educational activity is offered for a maximum of 1.2 KBN contact hours.

Provider #: 3-0008-01-18- 891. In order to receive credit, participants complete this CNE activity and submit a credit application and evaluation form online. Certificates may be printed once the evaluation is completed.

Other
UK Healthcare CECentral certifies this activity for 0.75 hours of participation.

Faculty Disclosure

Michelle Lofwalll, MD (planner) has relevant financial relationships with commercial interests as follows:

  • Braeburn Pharmaceuticals - Consultant and Principal Investigator - Consulting Fees and Research Contract
  • PCM Scientific - Speaker - Honoraria

No speaker or other planners have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speaker. In some cases, the presentation might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. The speaker will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

CE Content Concerns

Policy

Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504

Procedures

  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.